Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: Relationship with dyslipidaemia, inflammation, and factor VII genotype

Nephrology Dialysis Transplantation

Volumn 13, Issue 3, 1998, Pages 679-684

  Irish, Ashley B ^a   Green, Fiona R ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Chronic renal disease; Dyslipidaemia; Factor VII coagulant activity (VIIc); Factor VII genotype; Interleukin 6; Prothrombin fragment F1+2

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; FIBRINOGEN; INTERLEUKIN 6; LIPID; PROTHROMBIN; THROMBOPLASTIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; DYSLIPIDEMIA; GENOTYPE; HEART INFARCTION; HEMODIALYSIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; MAJOR CLINICAL STUDY; MONOCYTE; PRIORITY JOURNAL; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANTIGENS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; FACTOR VII; FEMALE; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RENAL DIALYSIS; RISK FACTORS;

EID: 0031886604     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.3.679     Document Type: Article

References (33)

1. Green D, Stone NJ, Krumlovsky FA. Putative atherogenic factors in patients with chronic renal failure. Progr Cardiovasc Dis 1983; 26(2): 133-143
2. Brown JH, Short CD, Mallick NP. Ischaemic heart disease, lipids and the kidney. In: Bourke E, Mallick NP. Pollak VE, eds. Moving Points in Nephrology. Karger, Basel, 1993; 198-219
3. Carvalho de Sousa J, Soria C, Ayrault-Jarrier M et al. Association between coagulation factors VII and X with triglyceride fractions. J Clin Pathol 1988; 41: 940-944
4. Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease. Principal results of The Northwick Park Heart Study. Lancet 1986; 2: 533-537
5. Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. Q J Medicine 1994; 87: 403-406
6. Rapaport SI, Rao LVJ. The tissue factor pathway: how it has become a 'Prima Ballerina'. Thromb Haemost 1995; 74(1): 7-17
7. Nachman RL. Thrombosis and atherogenesis. Molecular connections. Blood 1992; 79(8): 1897-1906
8. Holvoet P, Collen D. Oxidised lipoproteins in atherosclerosis and thrombosis. FASEB J 1994; 8: 1279-1284
9. Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med 1993; 119: 819-827
10. Mitropoulos K, Miller G, Watts G, Durrington P. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis 1992; 95: 119-125
11. Lane A, Cruickshank JK, Stewart J, Henderson A, Humphries S, Green F. Genetic and environmental determinants of factor VII coagulant activity in different ethnic groups at differing risk of coronary heart disease. Atherosclerosis 1992; 94: 43-50
12. Humphries S, Lane A, Green FR, Cooper J, Miller G. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscl Thromb 1994; 14(2): 193-8
13. Attman PA, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991; 39 [Suppl. 31]: S16-S23
14. Kario K, Matsuo T, Yamada T, Nakao K, Shimano C, Matsuo M. Factor VII hyperactivity in chronic dialysis patients. Thromb Res 1992; 67: 105-113
15. Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kidney Dis 1994; 23(6): 828-835
16. Cavagna R, Sciavon R, Tessarin C et al. Risk factors of ischemic cardiac disease in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 [Supp 2]: S402-S405
17. Kario K, Matsuo T, Matsuo M et al. Marked increase of activated factor VII in uremic patients. Thromb Haemost 1995; 73(5): 763-767
18. Miller GJ, Stirling Y, Esnouf MP et al. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bioassay to activated factor VII: an international study. Thromb Haemost 1994; 71(1): 38-48
19. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscl Thromb 1991; 11: 540-546
20. Boisclair MD, Philppou H, Lane DA. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. Blood Coag Fibrinol 1993; 4: 1007-1021
21. Rosenberg RD, Bauer KA. Prothrombin activation fragment assay. Clin Chem 1993; 39(4): 559-560
22. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest 1987; 80: 1527-1534
23. Mitropoulos KA, Miller GJ, Reevrs BEA, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203-208
24. Miller GJ, Martin JC, Mitropoulos KA et al. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. Atherosclerosis 1991; 86: 163-171
25. Silveira A, Green F, Karpe F, BlombŠck M, Humphries S, Hamsten A. Elevated levels of factor VII activity in the postprandial state: effect of the factor VII Arg-Gln polymorphism. Thromb Haemost 1994; 72(5): 734-739
26. Wilkes HC, Meade TW, Barzegar S et al. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability in patients with coronary heart disease. Thromb Haemost 1992; 67(5): 503-506
27. Avellone G, Di Garbo V, Cordova R et al. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia, Blood Coag Fibrinol 1995; 6: 543-548
28. Irish AB, Thompson CH. The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. Nephro Dial Transplant 1996; 11: 2223-2228
29. Le J, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61(6): 588-602
30. Stroes ESG, Joies JA, Chang PA, Koomans HA, Rabelink TJ. Impaired endothelial function in patients with nephrotic range proteinuria. Kidney Int 1995; 48: 544-550
31. Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strandgaard S. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol 1995; 5: 1581-1584
32. Gris JC, Branger B, Vecina F, Al Sabadini B, Fourcade J, Schved JF. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46: 807-813
33. Raine AEG, MacMahon SH, Selwood NH, Wing AJ, Brunner FP. Mortality from myocardial infarction in patients on renal replacement therapy in the UK. Nephrol Dial Transplant 1991; 6: 902